New Studies Further Evidence Link Between Actos and Bladder Cancer

Two new studies appear to further substantiate the link between Actos and bladder cancer, with one study indicating that the risk may be a trait of an entire family of diabetes drugs.

Two new studies appear to further substantiate the link between Actos and bladder cancer, with one study indicating that the risk may be a trait of an entire family of diabetes drugs.

In research published May 31, 2012 by the British Medical Journal, researchers found that Actos may double the risk of bladder cancer after two years, supporting recent warnings added to the medication about the risks associated with long-term use.  Specifically, the research suggests that the use of pioglitazone is associated with an increased risk of incident bladder cancer among people with type 2 diabetes.

The research team from Montreal, Canada reviewed the medical records of more than 110,000 patients who used diabetes drugs between 1988 to 2009. The research indicated that not only did the risk of bladder cancer substantially increase the longer one took Actos, but it also that the linkage appears to be dose-specific; that is, the higher one’s dose of Actos, the higher the likelihood of that person being diagnosed with bladder cancer.

In another study to be presented at the American Society of Clinical Oncology’s annual meeting, researchers suggested that the increased risk of bladder cancer may be associated with all drugs that belong to a class of medications known as glitazones, also known as thiazolidinediones, which includes Actos.

Researchers led by Ronac Mamtani, MD, of the University of Pennsylvania in Philadelphia reviewed data from 60,000 British patients who took glitazones for several years. The researchers found that after five years patients were at a 72% increased risk of developing bladder cancer.

In 2011 the U.S. Food and Drug Administration (FDA) issued a warning to U.S. consumers that Actos may be linked to an increased risk of bladder cancer, especially in patients who use the medication for more than one year. Patients who have bladder cancer are urged not to use Actos, while the medication should be used with caution in patients who have a prior history of bladder cancer, the FDA warns.  To learn more about the litigation against Takeda Pharmaceuticals (the manufacturer of Actos), contact a lawyer handling Actos lawsuits today.

Leave a Reply

 

Anti-Spam Protection by WP-SpamFree




Follow Us on:

Contact Us

Privacy Policy

Please click here to view our privacy policy.